生物相似藥市場按藥物類別、治療類型、分銷管道和地區分類

2025 年全球生物相似藥市場規模估計為 425.3 億美元，預計到 2032 年將達到 1,363.7 億美元，2025 年至 2032 年的複合年成長率為 18.1%。

圖。

全球生物相似藥市場的成長受到全球醫療成本的上漲和重磅生技藥品專利到期的推動。生物相似藥為癌症、糖尿病和自體免疫疾病等慢性病提供了經濟實惠的治療選擇。與參考生技藥品相比，生物相似藥可以顯著節省成本。例如，Filgrastim的生物相似藥 Zardio 的上市價格比原始生技藥品Neupogen 低 15%。美國、歐盟和日本等主要市場對生物相似藥的監管核准也在增加，並遵循明確的指導方針，簡化了生物相似藥的市場准入。這導致許多新興企業進入巨大且利潤豐厚的生物相似藥市場。

市場動態

全球生物相似藥市場的成長受到全球慢性病盛行率上升和醫療保健預算有限的推動。這推動了對生技藥品低成本生物相似藥替代品的需求。預計在 2018-2026 年預測期內，許多重磅生技藥品將失去專利保護，為生物相似藥打開大門。例如，到 2024 年，Infliximab和Adalimumab是面臨生物相似藥競爭的收益最高的生技藥品之一。大公司的監管核准、產品發布和擴大行銷活動可能會推動市場成長。

研究的主要特點

• 本報告對全球生物相似藥市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
• 它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球生物相似藥市場的主要企業。
• 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。
• 全球生物相似藥市場報告迎合了該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過全球生物相似藥市場分析中使用的各種策略矩陣來促進他們的決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• 一致的機會圖 (COM)

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管情景
• 收購和合作場景
• 資金籌措和投資
• PEST分析
• 波特的分析

第 4 章。

• 整體影響
• 政府舉措
• COVID-19 市場影響

5. 2020 年至 2032 年全球生物相似藥市場（按藥物類別分類）（十億美元）

• 介紹
• 重組人體生長荷爾蒙
• 顆粒細胞增生因子
• 胰島素
• 抗凝血劑
• 融合蛋白紅血球生成素
• 單株抗體
• 促濾泡素
• 其他

6. 2020 年至 2032 年全球生物相似藥市場（按治療類型分類）（十億美元）

• 介紹
• 腫瘤學
• 免疫學
• 血液學
• 荷爾蒙療法
• 代謝紊亂
• 其他

7. 2020-2032 年全球生物相似藥市場按通路分類（十億美元）

• 介紹
• 醫院藥房
• 零售藥局
• 專業藥房

8. 2020 年至 2032 年全球生物相似藥市場（按地區分類）（十億美元）

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭格局

• 公司簡介
  • Amgen Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Celltrion Healthcare Co., Ltd.
  • Biocon Limited
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Fresenius Kabi AG
  • Merck &Co., Inc.
  • Biogen Idec Inc
  • Coherus BioSciences
  • Stada Arzneimittel AG

第 10 章分析師建議

• 興衰
• 一致的機會地圖

第 11 章 參考文獻與調查方法

• 參考
• 調查方法

Global Biosimilars Market is estimated to be valued at USD 42.53 Bn in 2025 and is expected to reach USD 136.37 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.1% from 2025 to 2032.

Figure. Biosimilars Market Share (%), By Region 2025

Global biosimilars market growth is driven by rising healthcare costs worldwide and the expiration of blockbuster biologics patents. Biosimilars provide affordable treatment options for chronic diseases such as cancer, diabetes, and autoimmune disorders. These offer significant cost savings as compared to reference biologics. For example, Filgrastim's biosimilar Zarzio was launched at a 15% lower price compared to original biologic Neupogen. Regulatory approvals for biosimilars have also increased in major markets like the U.S, EU, and Japan following clear guidelines, thus, easing market entry. This has attracted many emerging players to the large and lucrative biosimilars market.

Market Dynamics:

Global biosimilars market growth is driven by factors like rising chronic disease prevalence rates worldwide coupled with limited healthcare budgets. This has boosted demand for lower-cost biosimilar alternatives to biologics. Many blockbusters biologic drugs are expected to lose patent protection over the forecast period 2018-2026, thus, offering potential for biosimilar entrants. For instance, infliximab and adalimumab are among the highest revenue earning biologics that faced biosimilar competition by 2024. Regulatory approvals and product launches, along with marketing expansion activities by major players can drive the market growth.

Key Features of the Study:

• This report provides in-depth analysis of the global biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global biosimilars market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novartis, Pfizer, Teva Pharmaceuticals, Celltrion, Biocon, Amgen, Samsung Biologics, Stada Arzneimittel AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biosimilars market.

Detailed Segmentation-

• By Drug Class
  • Recombinant Human Growth Hormone
  • Granulocyte Colony-Stimulating Factor
  • Insulin
  • Anticoagulants
  • Fusion Proteins Erythropoietin
  • Monoclonal Antibodies
  • Follitropin
  • Others
• By Therapy Type
  • Oncology
  • Immunology
  • Hematology
  • Hormone Therapy
  • Metabolic Disorders
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Amgen Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Celltrion Healthcare Co., Ltd.
  • Biocon Limited
  • Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Fresenius Kabi AG
  • Merck & Co., Inc.
  • Biogen Idec Inc
  • Coherus BioSciences
  • Stada Arzneimittel AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Therapy Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Biosimilars Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Biosimilars Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Recombinant Human Growth Hormone
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Granulocyte Colony-Stimulating Factor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Anticoagulants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fusion Proteins Erythropoietin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Monoclonal Antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Follitropin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Biosimilars Market, By Therapy Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oncology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hematology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hormone Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Metabolic Disorders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Biosimilars Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Biosimilars Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Company Profiles
  • Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Celltrion Healthcare Co., Ltd.
  • Biocon Limited
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Fresenius Kabi AG
  • Merck & Co., Inc.
  • Biogen Idec Inc
  • Coherus BioSciences
  • Stada Arzneimittel AG

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact

"